- Treatment with imatinib is associated with hematologic toxicity (anemia, neutropenia, and thrombocytopenia)

- Treatment with imatinib is associated with hepatotoxicity.

- Treatment with imatinib is associated with hypereosinophilic cardiac toxicity in patients with hypereosinophilic syndrome.

- Treatment with imatinib can cause fetal harm to a pregnant woman (Imatinib has demonstrated teratogenicity in rats at the 800 mg/day equivalent human maximum dose)

- Treatment with imatinib is associated with renal toxicity.

- Treatment with imatinib is associated with dermatologic toxicities, including erythema multiforme and Stevens-Johnson syndrome.